Current calls, week 8, 2023
Tips from KI Grants Office about current calls.
Swedish and Nordic calls
Forskningsbidrag - Linnéa och Josef Carlssons Stiftelse
Stiftelsen lämnar bidrag till vetenskaplig forskning med ändamål att hos barn och ungdomar med neurologiska handikapp förebygga, bekämpa och lindra sjukdomar, utvecklingsstörningar och skador av invalidiserande natur.
Closing date: March 31, 2023
Anslag till forskning rörande åderbråck eller andra vensjukdomar - Skandinaviska forskningsstiftelsen för åderbråck och vensjukdomar
Forskningsstiftelsen främjar vetenskaplig forskning och utveckling inom sjukdomar hos människan på grund av sviktande venfunktion, särskilt forsknings- och utvecklingsarbete inom sjukdomar i nedre extremiteterna. Forskning ska bedrivas med anknytning till universitet belägna i Skandinavien. Patientnära klinisk forskning kommer att premieras. Årets forskningsanslag uppgår till totalt 300 000 SEK som kan ansökas helt eller i delar.
Closing date: March 31, 2023
Stipendium - Svensk förening för Innovativ Kirurgisk Teknologi
Svensk förening för Innovativ Kirurgisk Teknologi, i samarbete med Braun, Olympus och Storz, inbjuder ansökningar om sina stipendier. Dessa syftar till att stimulera studier och utveckling inom endoskopisk kirurgi respektive inom föreningens verksamhetsområde.
Closing date: May 1, 2023
Industrial Doctoral Student 2023 – The Swedish Foundation for Strategic Research (SSF)
The aim of the call is to strengthen the collaboration between academia and industry. The grant runs during the education period for the doctoral students and must result in a doctoral degree.
SSF Industrial Doctoral program aims to contribute to excellent research in the prioritized areas of natural science, technology and medicine. The research must also promote cross-fertilization between academia and industry and contribute to the education of doctoral students in areas that are strategically relevant and strengthen Sweden’s competitiveness. The initiative applies to people who have not yet been admitted to postgraduate studies. During the grant period, the doctoral student must conduct research and be at least 80 percent employed at a company, as well as have two supervisors, one at the university and one at the company. The institution must be Swedish. The main applicant is the supervisor of the doctoral student at the University. Co-applicants are supervisors at the company. If the project involves clinical research, the company can be a hospital. SSF intends to fund 12 projects of SEK 2.5 million each (including indirect costs).
Closing date: May 23, 2023
Projektansökningar - Promobilia Stiftelsen
Stiftelsen finansierar forskning och utveckling inom alla typer av funktionsnedsättningar, gärna projekt som ligger nära nyttiggörande. Tekniska lösningar är av extra intresse.
Closing date: March 20, 2023
European calls
EFSD/Boehringer Ingelheim European research programme on multi-system challenges in diabetes
European Foundation for the Study of Diabetes (EFSD)
The European Foundation for the Study of Diabetes and Boehringer Ingelheim invite applications for their European research programme on multi-system challenges in diabetes. This supports projects that advance current knowledge in the inter-organ crosstalk and related pathophysiology in diabetes and its complications through innovative basic or clinical research, and assess the adaptation and impact of guidelines directed medical care in management of diabetes. Research will be supported through the award of research grants up to Euro 100,000 for basic and/or clinical research projects with the exclusion of clinical trials.
Closing date: 12 April 2023
Start-up grants - AO Foundation, Switzerland
The AO Foundation invites pre-proposals for its start-up grants. These support young scientists and clinicians in the field of spine research, including both clinical and translational research. Grants provide research seed funding of up to CHF 25000 for one year.
Closing date: 01 April 2023
ECCO pioneer award - European Crohn's and Colitis Organisation
The European Crohn’s and Colitis Organisation (ECCO) offers Research Awards to encourage and support innovative basic and/or clinical scientific research in the area of Inflammatory Bowel Diseases (IBD) across Europe. ECCO Pioneer Awards are designed to support visionary, interdisciplinary scientific research in IBD. Applications can be as a single centre (including single PI applications) or a multicentre project group. Applicants need to be ECCO Members at the submission deadline.
Closing date: 01 May 2023
ECCO grants - European Crohn's and Colitis Organisation
The European Crohn’s and Colitis Organisation (ECCO) offers Research Grants to encourage and support early career individuals and promote innovative scientific research in the area of Inflammatory Bowel Diseases (IBD) in Europe. ECCO Grants are designed to support IBD Research within the country of affiliation. Typically, research for ECCO Grant projects is undertaken in the home institution of the applicant.
The target audience are early career basic/clinical scientists who are:
- not yet 40 years old at the submission deadline, or
- 40 years or older, who are within five years of the date of completion of their GI training or PhD graduation
A total of EUR 80.000 will be awarded per ECCO Grant. The Grant funds can be spent on consumables and/or salary
Closing date: 01 May 2023
US calls
Federal Funding
Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)
Funder: National Institutes of Health (NIH)
United States Department of Health and Human Services (HHS)
Funder's opportunity IDs: PAR-22-137, PAR-22-138
Upcoming deadlines: Standard dates apply.
Deadline Note: Applications due by 5:00 PM local time of applicant organization
Abstract: The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).
Advancing methods for safe, noninvasive, real time assessment of placenta development and function across pregnancy (R21 clinical trial not allowed)
Funder: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institutes of Health (NIH)
United States Department of Health and Human Services (HHS)
Funder's opportunity ID: PAR-22-236
Upcoming deadlines: Standard dates apply.
Abstract: The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its advancing methods for safe, noninvasive, real time assessment of placenta development and function across pregnancy (R21 clinical trial not allowed) funding opportunity. This aims to advance or clinically validate emerging novel approaches for the development of safe, real-time, non-invasive (or minimally invasive) methods to assess the development and function of the human placenta across pregnancy.
Ref: PAR-22-236.
Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
Funder: National Cancer Institute (NCI)
National Institutes of Health (NIH)
United States Department of Health and Human Services (HHS)
Funder's opportunity IDs: PAR-22-061, PAR-22-062
(Re-issue of PAR-19-199)
Upcoming deadlines: Standard dates apply.
Deadline Note: Applications due by 5:00 PM local time of applicant organization
Abstract: The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies.
Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter their effectiveness and thus those parameters should be rigorously addressed in the application.
Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Funder: National Institute of Mental Health (NIMH)
National Institutes of Health (NIH)
United States Department of Health and Human Services (HHS)
Funder's opportunity IDs: PAR-23-097, PAR-23-102
(Re-issue of PAR-22-036)
Upcoming deadlines: Standard dates apply.
Deadline Note: All applications are due by 5:00 PM local time of applicant organization.
Abstract: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts.
NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)
Funder: National Eye Institute (NEI)
National Institutes of Health (NIH)
United States Department of Health and Human Services (HHS)
Funder's opportunity ID: PAR-22-141
(Re-issue of PAR-19-260)
Upcoming deadlines: Standard dates apply.
Deadline Note: Applications due by 5:00 PM local time of applicant organization
Abstract: This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.
Foundation grants
Funder: International Anesthesia Research Society (IARS)
Upcoming deadlines:
Date: 30 Apr 2023 - Confirmed / sponsor
What's due: Application - required
Amount: Upper: $175,000 USD
Up to four research projects are selected annually, with a maximum award of $175,000 each, payable over two years. Indirect expenses will not be funded.
Eligibility: Principal applicants for IMRA must be members of the IARS who have yet to establish substantial independent research funding or who are initiating a new area of research. Duration since completion of clinical training or PhD must be under 10 years. Applicants must have a minimum of 45% protected non-clinical time.
Abstract: These support clinical, translational or basic science that is relevant to the broad practice of anaesthesiology and its subspecialties. The aim is to support investigations that will further the understanding of clinical practice in anaesthesiology and related sciences. Grants are intended to help create future leaders and prepare applicants to apply for independent research funding.
Funder: CurePSP - Foundation for PSP/CBD and Related Brain Diseases
Upcoming deadlines:
Date: 17 Mar 2023 - Confirmed / sponsor
What's due: Application - required
Amount: Upper: $100,000 USD
The maximum total grant amount awarded is $100,000. The period of the grant may be up to 3 years in duration but the total cannot exceed $100,000. However, greater or lesser amounts and duration may be offered depending on resources available. Indirect expenses will not be funded.
Eligibility: CurePSP accepts proposals for research projects from academic and non-academic institutions. All PIs must have an academic degree in science, social work, engineering, or medicine such as a ScD, PhD, MD, MD/PhD, DO, DSW, and DVM degree.
Abstract: CurePSP promotes research that helps generate an integrated picture of PSP and CBD at pre-clinical and clinical levels. CurePSP believes that in the long term, research of this nature will prove indispensable in developing a prevention or cure for PSP, CBD, and other prime of life diseases. CurePSP will fund studies on PSP and CBD with a particular interest in (i) molecular and cellular (pathological) mechanisms that may operate also in related diseases and (ii) translational clinical research involving PSP and CBD patients.
Funder: Human Frontier Science Program Organization (HFSPO)
Upcoming deadlines:
Date: 21 Mar 2023 - Confirmed / sponsor
What's due: Other - required
Compulsory initiation of a letter of intent by obtaining a reference number
Date: 30 Mar 2023 - Confirmed / sponsor
Whats due: Letter of Intent - required
Deadline Note: Submission of full applications: mid-September, on invitation only
Amount: Upper: $500,000 USD Lower: $150,000 USD
Grants are worth between USD 150,00 and USD 500,000 depending on the number of team members, for a total period of three years. Indirect expenses up to 10% will be funded.
Eligibility: HFSP Research Grants support teams of independent leaders of research groups. Therefore, applications from individual scientists or early career researchers carrying out their postdoctoral or PhD level projects are not eligible.
Abstract: HFSP Research Grants support innovative basic research into fundamental biological problems with emphasis placed on novel and interdisciplinary approaches that involve scientific exchanges across national and disciplinary boundaries. Research grants are provided for teams of scientists from different countries who wish to combine their expertise in innovative approaches to questions that could not be answered by individual laboratories. Preliminary results are not required and applicants are expected to develop new lines of research through the research collaboration.
Two types of Grant are available:
- Research Grants – Program (RG-Program): to allow teams of independent researchers to develop new lines of research through a new collaboration, with applications including independent investigators early in their careers being particularly encouraged
- Research Grants – Early Career: to enable teams of young investigators who are directing a research group to initiate and direct their own independent lines of research.
New Academic Investigators Program
Funder: Target ALS
Upcoming deadlines:
Date: 17 Mar 2023 - Confirmed / sponsor
What's due: Letter of Intent - required
Amount: Upper: $390,000 USD Lower: $260,000 USD
- $130,000 per year for three years, for a total possible grant of $390,000. The initial grant will be for a two-year period. A lab will be eligible to compete for a third year of funding based on a competitive review of updated project goals as well as compelling progress at the end of second year of funding.
Eligibility: Individual investigators (M.D.s or Ph.D.s) who have established their independent lab in an academic institution within the last five years.
Abstract: Target ALS is focused on identifying and supporting ideas of the next generation of ALS research leaders through the New Academic Investigators program.
Target ALS is especially interested in proposals that apply novel methods to tackle fundamental questions of biology, drug development, and biomarker identification for ALS or ALS/FTD. Target ALS is looking to support projects that propose:
- Identification, validation, and development of new targets for therapeutics; or
- Development of biomarkers, tools, and technologies to facilitate human proof-of-biology studies.